May 21 |
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
|
May 14 |
Aerovate Therapeutics reports Q1 GAAP EPS of -$0.83
|
May 13 |
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
|
Apr 4 |
Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares
|
Mar 27 |
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
|
Mar 27 |
Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023
|
Mar 25 |
Aerovate Therapeutics reports FY results
|
Mar 25 |
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
|
Mar 21 |
Chief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc (AVTE)
|
Mar 21 |
Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ...
|